|Bid||184.99 x 800|
|Ask||185.03 x 800|
|Day's Range||183.34 - 185.39|
|52 Week Range||142.81 - 237.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||2.88 (1.71%)|
|1y Target Est||208.45|
As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.
Allergan (AGN) is a leading specialty pharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biological products.
A stock's price can fall for many reasons. The company may no longer be performing as it's expected to. The industry or sector could be temporarily out of fashion. Sometimes, a weak market simply pulls good stocks down with it. As long as the issue isn't fundamental (and long-term), you can still buy low and eventually sell high, even in a toppy market like today's. Today, we will look at 10 stocks with market caps between $10 billion and $200 billion that have fallen hard in the past year, but that some analysts think are poised for a bounce-back. These companies are in a variety of industries - everything from banking to pharmaceuticals to industrial products to consumer goods. Clearly, each of these stocks comes with some risk given the bearish drivers that have dragged them down by 20%, 30%, even 40%. But investors should be less concerned about why these stocks fell in the past, and more concerned about whether they realistically can rebound from here. None of these stocks need to reach their old highs for investors to neatly profit - the underlying companies just need to follow through on proposed ways to increase shareholder value. Here's a look at 10 battered stocks to buy for their recovery potential. SEE ALSO: 20 of the Best Stocks You Probably Haven't Heard Of
Bausch Health Companies’ (BHC) wholly-owned subsidiary Salix Pharmaceuticals reported revenue of $441 million in the second quarter compared to $387 million in the second quarter of 2017, which reflected ~14% YoY (year-over-year) growth.
In the first half of 2018, Bausch Health reported revenue of $4.1 billion compared to $4.3 billion in the same period last year. Bausch Health reported net income of -$873 million in the second quarter compared to -$38 million in the same period last year. In the first half of 2018, Bausch Health reported net income of -$3.45 billion compared to -$590 million in the same period last year.
After the first half of 2018, Bausch raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. In August, Bausch Health’s wholly owned subsidiary Salix Pharmaceuticals and US WorldMeds announced the launch of Lucemyra 0.18 mg tablets in the US market. Right now, Lucemyra is the first and only non-opioid drug indicated for the mitigation of opioid withdrawal symptoms for facilitating rapid opioid discontinuation in adults.
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
The genome-editing specialist just offered its latest update on the state of the business. Here's what investors need to know.
Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.
DUBLIN, Aug. 8, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that Michael E. Greenberg, PhD will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Dr. Greenberg is the Nathan Marsh Pusey Professor of Neurobiology at Harvard University and the Co-Lead of the Allen Discovery Center for Human Brain Evolution at Harvard Medical School.
Bausch Health Companies stock was trading at $24.39 today, an ~8.40% increase from yesterday’s close of $22.50. On August 6, Bausch Health stock closed at $22.50, which represents a ~106% increase from its 52-week low of $10.94 on November 2, 2017. After Q2 2018 financial results, Bausch Health Companies raised its full-year adjusted EBITDA guidance from $3.15 billion–$3.30 billion to $3.20 billion–$3.35 billion. Bausch Health anticipates net revenues for the fiscal year 2018 to be in the range of $8.15 billion and $8.35 billion.
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.
Elanco is Eli Lilly & Co.’s (LLY) animal health business. Elanco reported revenues of $792.1 million in the second quarter, representing 1.0% YoY (year-over-year) growth from $784.8 million in the second quarter of 2017. The chart below shows Elanco’s revenues since the first quarter of 2017.
Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash. The deal will make dermatology into Almirall's main growth driver, increasing the business's net sales to nearly 45 percent of the group total from 34 percent, Almirall said. "This is a transformational deal for Almirall.